Literature DB >> 24197881

Rapid detection of Staphylococcus aureus strains with reduced susceptibility to vancomycin by isothermal microcalorimetry.

J M Entenza1, B Bétrisey, O Manuel, M Giddey, O Sakwinska, F Laurent, A Bizzini.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) usually harbors a vancomycin-susceptible phenotype (VSSA) but can exhibit reduced vancomycin susceptibility phenotypes that can be heterogeneous-intermediate (hVISA), intermediate (VISA), or fully resistant (VRSA). Current detection techniques (e.g., Etest and population analysis profiles [PAPs]) are slow and time-consuming. We investigated the potential of microcalorimetry to detect reduced susceptibilities to vancomycin in MRSA strains. Representative MSSA, VSSA, hVISA, VISA, and VRSA reference strains, as well as clinical isolates, were used. PAPs were performed by standard methods. Microcalorimetry was performed by inoculating 5 × 10(7) CFU of overnight cultures into 3-ml vials of brain heart infusion broth supplemented with increasing concentrations of vancomycin, and growth-related heat production was measured at 37°C. For the reference strains, no heat production was detected in the VSSA isolates at vancomycin concentrations of >3 μg/ml during the 72 h of incubation. The hVISA and VISA strains showed heat production with concentration-proportional delays of up to 6 μg/ml in 48 h and up to 12 μg/ml in 72 h, respectively. The VRSA strain showed heat production at concentrations up to 16 μg/ml in 12 h. The testing of clinical strains indicated an excellent negative predictive value, allowing us to rule out a decreased vancomycin susceptibility phenotype in <8 h of incubation. Sequential isolates from a patient undergoing vancomycin therapy showed evolving microcalorimetric profiles up to a VISA phenotype. Microcalorimetry was able to detect strains with reduced susceptibilities to vancomycin in <8 h. The measurement of bacterial heat production might represent a simple and rapid method for the detection of reduced susceptibilities to vancomycin in MRSA strains.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24197881      PMCID: PMC3911443          DOI: 10.1128/JCM.01820-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

2.  Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains.

Authors:  Zahra Moravvej; Fatemeh Estaji; Emran Askari; Kavous Solhjou; Mahboobeh Naderi Nasab; Sareh Saadat
Journal:  Int J Antimicrob Agents       Date:  2013-07-21       Impact factor: 5.283

3.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

4.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  Analysis of microcalorimetric curves for bacterial identification.

Authors:  D López; M Viñas; J G Lorén; J Bermúdez
Journal:  Can J Microbiol       Date:  1987-01       Impact factor: 2.419

6.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.

Authors:  M Wootton; R A Howe; R Hillman; T R Walsh; P M Bennett; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

Review 7.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

8.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

9.  Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

Authors:  Longzhu Cui; Eiji Tominaga; Hui-Min Neoh; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.

Authors:  Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

View more
  11 in total

1.  The Slow March toward Rapid Phenotypic Antimicrobial Susceptibility Testing: Are We There Yet?

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 2.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

Review 3.  Recent Advances in the Use of Molecular Methods for the Diagnosis of Bacterial Infections.

Authors:  Elisabetta Gerace; Giuseppe Mancuso; Angelina Midiri; Stefano Poidomani; Sebastiana Zummo; Carmelo Biondo
Journal:  Pathogens       Date:  2022-06-08

Review 4.  Mechanisms and clinical relevance of bacterial heteroresistance.

Authors:  Dan I Andersson; Hervé Nicoloff; Karin Hjort
Journal:  Nat Rev Microbiol       Date:  2019-06-24       Impact factor: 60.633

5.  Activity of daptomycin- and vancomycin-loaded poly-epsilon-caprolactone microparticles against mature staphylococcal biofilms.

Authors:  Inês Santos Ferreira; Ana F Bettencourt; Lídia M D Gonçalves; Stefanie Kasper; Bertrand Bétrisey; Judith Kikhney; Annette Moter; Andrej Trampuz; António J Almeida
Journal:  Int J Nanomedicine       Date:  2015-07-07

6.  Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections.

Authors:  Delphine Héquet; Georg Kralidis; Thierry Carrel; Alexia Cusini; Christian Garzoni; Roger Hullin; Pascal R Meylan; Paul Mohacsi; Nicolas J Mueller; Frank Ruschitzka; Piergiorgio Tozzi; Christian van Delden; Maja Weisser; Markus J Wilhelm; Manuel Pascual; Oriol Manuel
Journal:  BMC Infect Dis       Date:  2016-07-08       Impact factor: 3.090

Review 7.  Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs.

Authors:  Florian P Maurer; Martin Christner; Moritz Hentschke; Holger Rohde
Journal:  Infect Dis Rep       Date:  2017-03-30

8.  Essential Oils Biofilm Modulation Activity, Chemical and Machine Learning Analysis. Application on Staphylococcus aureus Isolates from Cystic Fibrosis Patients.

Authors:  Rosanna Papa; Stefania Garzoli; Gianluca Vrenna; Manuela Sabatino; Filippo Sapienza; Michela Relucenti; Orlando Donfrancesco; Ersilia Vita Fiscarelli; Marco Artini; Laura Selan; Rino Ragno
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 9.  Assessing Viability and Stress Tolerance of Probiotics-A Review.

Authors:  Ulrika Wendel
Journal:  Front Microbiol       Date:  2022-01-27       Impact factor: 5.640

Review 10.  Modern Tools for Rapid Diagnostics of Antimicrobial Resistance.

Authors:  Antti Vasala; Vesa P Hytönen; Olli H Laitinen
Journal:  Front Cell Infect Microbiol       Date:  2020-07-15       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.